Raymond James Maintains Outperform on Harmony Biosciences, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has maintained an Outperform rating on Harmony Biosciences (NASDAQ:HRMY), but lowered the price target from $58 to $26.
October 16, 2023 | 8:21 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Raymond James has maintained an Outperform rating on Harmony Biosciences, but lowered the price target from $58 to $26.
The news is directly related to Harmony Biosciences. While the Outperform rating is positive, the significant reduction in price target could create uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100